Foliculin Special Precautions

Before starting treatment, the couple's infertility should be assessed as appropriate and putative contra-indications for pregnancy evaluated.
Adherence to the recommended dosage and monitoring schedules will minimize the possibility of ovarian hyperstimulation syndrome.
Excessive ovarian response to Foliculin treatment does generally not induce significant adverse effects except if hCG is administered for ovulation induction or if pregnancy occurs; ovarian hyper stimulation syndrome occurs usually 1 to 2 weeks following hCG administration and ovulation.
In case of symptoms such as pelvic pain, abdominal distension or ovarian enlargement or if oestrogen assays or ultrasound examinations suggest an excessive oestrogenic response, Foliculin administration should be discontinued and hCG should not be administered and intercourse avoided in order to prevent ovarian hyperstimulation.
Ascites, pericardial effusion, hydrothorax, hemo-concentration, secondary hyperaldosteronism or hypercoagulability might appear. These symptoms should be controlled through appropriate medical measure, including avoidance of unnecessary pelvic examination. In the absence of pregnancy, they usually resolve spontaneously with the onset of the menses.
Effects on ability to drive and use machine: No studies on the effects on the ability to drive and use machines have been performed. However, Foliculin is unlikely to have influence on the patient's performance to drive and use machines.